12 Best Long Term Low Risk Stocks to Buy Right Now

Page 6 of 12

7. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81 

Johnson & Johnson (NYSE:JNJ) researches and develops, manufactures, and sells various products in the healthcare field. In Q4 2024, the company reported sales of $22.5 billion, marking a 5.3% increase from the previous year. Operational growth was 6.7%, with adjusted operational growth at 5.7%. For the full year 2024, the firm achieved total sales of $90.8 billion, representing a 6.6% increase compared to 2023. Operational growth for the year was 7.2%, with adjusted operational growth at 6%. The company has recently announced plans to acquire Intra-Cellular Therapies, a developer of mental health treatments, for approximately $15 billion. This acquisition aims to bolster Johnson & Johnson’s pharmaceutical portfolio, particularly in the neuroscience sector.

Page 6 of 12